SAR442168 (tolebrutinib) is an orally bioavailable, brain-penetrant, selective, small-molecule inhibitor of Bruton's tyrosine ...

Keeping up with scientific advances and practice changes can be one the biggest challenges in managing a complex disease like multiple sclerosis (MS).

Tolebrutinib slows disability progression in adults with nonrelapsing secondary progressive multiple sclerosis (MS).

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis.

Two researchers win the Breakthrough Prize in Life Sciences for their discoveries related to multiple sclerosis disease ...

Frexalimab was well tolerated and maintained disease control over two years in adults with relapsing MS in an open-label ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...